Connect with us
Subscribe

Press Releases

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

Published

on

Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection

Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies.

Builds on 2018 agreement to jointly develop an mRNA-based influenza vaccine                        

United Arab Emirates, March 18, 2020 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. 

The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza. 

“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible.” 

“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a COVID-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of BioNTech.

The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.

The companies will begin collaborating immediately. They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks. 

On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

About Pfizer: Breakthroughs That Change Patients’ Lives 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. 

Pfizer Disclosure Notice: 

The information contained in this release is as of March 17, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BioNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, whether and when a definitive agreement will be reached for the co-development and co-commercialization by Pfizer and BioNTech of BNT162 ; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when any biologics license applications may be filed in any other jurisdictions for BNT162 or any other vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether BNT162 will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BNT162; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding BNT162 and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.  The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer.  For more information, please visit www.BioNTech.de.

Forward-looking statement

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, the ability of BioNTech to develop and commercialize a vaccine for COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BionNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial of BNT162. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for Covid-19 and potential difficulties. For a discussion of these and other risks and uncertainties, see the section entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in BioNTech’s Registration Statement on Form F-1 filed with the SEC on September 9, 2019, as amended, which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Contact:

Media Relations

Anand George Zachariah

+971 4 330 4010 ext.455 or +971 55 3766809

anandgeorge.zachariah@fleishmaneurope.com

Continue Reading
Click to comment

Articles

Wellbeing @ Work Summit Middle East 2021 – where balance, resilience and authenticity break the Mental Health Stigma

Published

on

Written by: Cinzia Nitti

Globally, 2020 has been a year like no other. Coronavirus pandemic caused a massive business disruption; transformation has been key in supporting employees and catalyzing workplace changes. There was a rush to adapt and reinvent Business Models. Organizations had to rethink and reconsider how they deliver services and strengthen their Organizations through a forward-thinking Digital strategy. To be more agile and responsive in such uncertain times, we need to respond to challenges and adapt quickly to new scenarios by moving from rigid hierarchies to leaner and more flexible structures.

But what about Mental Health at Work, and why is it essential?

What’s the Office of the Future?

Within the Wellbeing @ Work Summit Middle East 2021, HR Leaders tried to normalize the conversation about Mental Health by putting the topic first, enabling self-care and professional support, raising awareness, and building knowledge around its related issues. Nowadays, personal and work life are more intertwined than ever, so it becomes vital to create balance: the more employees feel free to talk about Mental Health, the more they can prevent struggle and breakout at the Workplace. HR leaders play a crucial role in making an IMPACT by pushing new solutions, promoting work-life balance, redesign workloads, and supporting their Teams.

In this general frame, Irada Aghamaliyeva (MENA Diversity, Inclusiveness & Wellbeing Leader at EY) affirmed: “Workplaces that are inclusive foster enhanced employee wellbeing; employees with high levels of wellbeing are more inclusive”. How can Organizations increase employees’ resilience and embed sustainable Leadership behaviors in the post-covid reality?

Dr. Irada Aghamaliyeva introduced the Mindfulness practice in the Workplace and highlighted its benefits on a large scale: improved wellbeing and resilience on a physical level; positive emotions, self-regulation, empathy and awareness of social dynamics; learning and innovation thanks to the implementation of flexible thinking, intuition and problem-solving processes. So breaking the stigma is possible, starting from personal wellbeing to sustain positive energy and fuel resilience.

About the Power of Empathetic and Authentic Leadership, Dr. Rima Ghose Chowdhury (EVP & Chief Human Resources Officers at Datamatics Global Services) stresses the importance of Leadership roles today. The virtual environment employees are working in, makes them more vulnerable due to a lack of balance between emotional and authenticity traits. Authenticity is the primary factor in effective leadership, regardless of the leadership style. Putting employees first as a strategic priority and hearing their voices to guide strategy; embracing agility to work more effectively in tumultuous time; including a multigenerational work-force: these are the key concepts within Dr. Rima’s motto “Empowering is to enable”. Through motivation and filling emotional support needs, the Empowering Teams Process leads to employees’ safety, esteem, and self-actualization. 

The Wellbeing @ Work Summit delivers strategic direction, advice and inspiration from employers and experts from across the world to help you create a more compassionate corporate culture that delivers results. To know more about the FOW Future of Work Insights platform around the world, click here: https://fowinsights.com/

Continue Reading

Press Releases

Gulf Sustainability Awards are open for entries

Published

on

HR Revolution Middle East has been announced as an official media partner of the 2021 Gulf Sustainability Awards.

Taking place in Dubai on September 20, 2021, the new-look Gulf Sustainability Awards will celebrate the very best in sustainable practice and environmental, social, and corporate governance in the MENA region.

Hosted by Awards International, the Gulf Sustainability Awards 2021 offers entrants 14 categories in which to submit a written entry.

That will then be judged by an independent panel of business experts with a focus on sustainability, ESG, and CSR. A shortlist of finalists with the highest scores will then be revealed, with a team of representatives from each organisation invited to present their initiatives live at the awards final.

Judges will score presentations on the day, and category winners – alongside 2021’s Overall Winner – will be revealed at a glittering live awards ceremony, hosted by a very special guest.

Welcoming HR Revolution  Middle East on-board as a media partner, Awards International’s Regional Manager for the Middle East, Aleksandar Ilić, said: “We are thrilled to be joined by HR Revolution for our new look Gulf Sustainability Awards.

“Having the support and influence of the MENA region’s premier human resources portal is a major asset in our aim of celebrating corporate social responsibility, as HR is crucial to ensuring success in that field, especially around the category focusing on the best workplace and HR practices.

“We can’t wait to discover the sustainability and CSR strategies that are changing the face of business practise in the Gulf, and we are excited to be welcoming the most dedicated organisations to compete, live, in Dubai later this year.”

To discover more about sponsoring and partnership opportunities at the 2021 Gulf Sustainability Awards, visit the official website.

Continue Reading

Magazine

WELLBEING @ WORK SUMMIT 22-24 FEBRUARY 2021 MIDDLE EAST

Published

on

Now is the time to make wellbeing & mental health at work a strategic priority

The fifth annual Wellbeing @ Work Middle East Summit returns for a virtual festival on 22-24 February 2021. The three-day Summit is for HR, Wellbeing, Benefit and Business Leaders from across the Middle East who are facing business critical employee wellbeing and mental health challenges and those leaders who want to take their wellbeing and mental health strategies to the next level.

It is time to build back successfully with a people first agenda and an impressive speaker line-up awaits attendees who will also have full access to an unrivalled AI enabled virtual platform where they can connect and meet with other like-minded delegates for world-class networking two weeks leading up the Summit.

Delegates can hear and engage with leading employers and workplace experts from across the world including the Global Human Resources Director from Daraz (Alibaba Group), Chief Human Resources Officer at Jumeriah Group, Global Belonging Lead Mental Health from Spotify, Director of Human Resources at NEOM, Director of Human Resources at Zain Bahrain, Group Head of Talent Acquisition at Chalhoub Group, Global HR Director and D&I Lead for MEA from Schneider Electric and the Global Leader of Diversity & Inclusion from Nielsen to name just a few.

In addition to expert content, attendees will be provided with invaluable workshops on specific areas of delivering a successful workplace wellbeing strategy, up to the minute data and case studies from the world’s leading employers and entertainment throughout the three-day festival. 

Sonas Group CEO, Chris Cummings said ‘Whilst mental health and wellbeing in the workplace was rising in importance in recent years, 2020 was the year when every organization had to prioritise the health of their employees. Companies who want to build back successfully must prioritize the mental health and wellbeing of their people and the Wellbeing @ Work Summit provides the tools, advice and information business leaders need to achieve this effectively’.

After a seismic shift last year, The Wellbeing @ Work Summit delivers strategic direction, advice, and inspiration from employers and experts from across the world to help create a more compassionate corporate culture that delivers results. The design and implementation of a holistic wellbeing and mental health programme that delivers healthy outcomes and a more productive organisation is paramount right now.

For further information, registration details and group discounts to attend the Summit, please visit the event website here or email the Delegate Manager Paula Taker paula.tasker@sonasevents.com

Notes to Editor:

The Wellbeing @ Work Summits are annual conferences taking place across the world and organized by Sonas Group Ltd. For further information, please contact

Chris Cummings, CEO, Sonas Group

Chris.cummings@sonasevents.com

Continue Reading

HRCI

HRCI

Recent Posts

Articles1 week ago

Wellbeing @ Work Summit Middle East 2021 – where balance, resilience and authenticity break the Mental Health Stigma

Written by: Cinzia Nitti Globally, 2020 has been a year like no other. Coronavirus pandemic caused a massive business disruption;...

Articles4 weeks ago

The Wellbeing @ Work virtual Summit Middle East returns for its 5th annual event on 22-24 February 2021

The summit provides an innovative and experiential virtual learning opportunity for our audience of CEOs, benefit and reward business leaders...

Interviews1 month ago

Interview with Keith F Watson -Online Tutor ICS Learn

“We feature our student success stories in our monthly Student Newsletter, as we know this inspires learners to keep going...

Press Releases1 month ago

Gulf Sustainability Awards are open for entries

HR Revolution Middle East has been announced as an official media partner of the 2021 Gulf Sustainability Awards. Taking place...

Interviews1 month ago

Interview with Mohamed Faisal Al-Nizami, Country Manager at Mercer Egypt

“Nowadays, Reward in specific is one of the hottest topics that keeps execs busy, in a world that is shifting...

Interviews2 months ago

Interview with Dr. Sanjay Batheja, the Co-Founder and Director of Capital University College

“Capital University College believes in fostering young talent by giving students an international perspective and ideology to the industry. With...

Interviews2 months ago

Interview with Mr. Ishaq Ameen Alkooheji, Founder & Senior Consultant at IMA Consultancy

“The ROI methodology can be used for not only measuring the impact and ROI, but also for planning for better...

Magazine2 months ago

WELLBEING @ WORK SUMMIT 22-24 FEBRUARY 2021 MIDDLE EAST

Now is the time to make wellbeing & mental health at work a strategic priority The fifth annual Wellbeing @...

Corporate2 months ago

Interview with Mr. Vijay Gandhi, Regional Director of Korn Ferry Digital

“2021 is here and there has been never a tipping point like this before for governments and organizations to transform...

Magazine3 months ago

DECODING FUTURE HR: Global 24 hour virtual event | 19 and 20 January 2021

DECODING FUTURE HR: Today’s challenges are tomorrow’s trends and opportunities Global 24 hour virtual event | 19 and 20 January...

ICS Learn

ICS Learn

Categories

Trending

Hrrevolution News

Subscribe to our weekly newsletter below and never miss the latest News.